Cergutuzumab amunaleukinCANCT02004106metastatic/unresectable CEA+ solid tumors
…Background Cergutuzumab amunaleukin (CA) is an immunocytokine comprising an anticarcinoembryonic an…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 721–780 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Dapsone5Diclofenac5Epirubicin5FibroScan5Hyperbaric bupivacaine5ICB5ICS/LABA5IFNγ5IL-185SARS-CoV-25donanemab5immunomodulators5low-dose aspirin5tapentadol5thiazolidinediones56-mercaptopurine5High-dose steroids5JAK inhibitors5Letrozole5Mercaptopurine5Steroid5Trastuzumab Emtansine5Vitamin B125antiseizure medication5candesartan5ganciclovir5immune checkpoint inhibitor5non-steroidal anti-inflammatory drug5normal saline5nortriptyline5supplemental oxygen5ASMs5Atracurium5Bacillus Calmette-Guérin5Bendamustine5High-dose intravenous methylprednisolone5SF-365Selective Serotonin Reuptake Inhibitors5acetic acid5contraceptives5delpar5intravenous ceftriaxone5liposomal amphotericin B5prescription opioids5topical corticosteroids5venlafaxine5DPP4i4ELA4Estrogen4Rilvegostomig4HM163904Alectinib4Penumbra4RP14LEvoSimendan4Nipocalimab4Dinutuximab4SEL4BLM4IL-17i4
Articles mentioning drugs
10,506 articles · page 168 of 876NT-proBNPtertiary cardiovascular disease centreSTEMIacute ST-segment elevation myocardial infarction
…8).Conclusions In a cohort of stabilised acute STEMI survivors, NT-proBNP was associated with all-cause mid-term mortality independent of…
CytisiniclineCOPDchronic obstructive pulmonary diseasebehavioural support
…for COPD and 32.6% versus 8.6% (OR 5.2, p<0.0001) for non-COPD. Cytisinicline was well tolerated with no serious treatment-related events.Con…
DoxyPEPDoxycyclinesyphilischlamydiagbMSM
…STI prevention, over one-quarter of participants reported using DoxyPEP, with high awareness and demand for structured access. These fi…
ACE inhibitorsdiureticsbeta-blockerssodium-glucose cotransporter 2 inhibitorscardiac stimulantsglucagon-like peptide-1 receptor agonistsphlebotomycardiac resynchronisation therapyheart failureHF
…hese neurohumoral pathways, most notably with beta-blockers and ACE inhibitors. At present, HF is defined as ‘a clinical syndrome with signs a…
APERIO HybridAPERIOICHmedium vessel occlusionsMeVOs
…(15%). Overall recanalization success was 95.8%. TICI 2b/3 with APERIO Hybrid was achieved after the first pass in 76 patients (63.9%), in 23…
bevacizumab-SIACIbevacizumabcetuximab-SIACIcetuximabmannitolndGBMrGBMglioblastoma
…e completed successfully. Forty-one patients with rGBM received bevacizumab-SIACI, 7 with ndGBM bevacizumab-SIACI, and 22 with ndGBM cetuximab-SI…
AzithromycinAzithromycineBill and Melinda Gates FoundationINV-005395childhood mortalityChild Health Days
…Background Azithromycin mass drug administration (MDA) to ages 1–59 months can reduce c…
99.5%
Risankizumabustekinumabustekinumab-naiveustekinumab-exposedCrohn’s diseaseUK licensing authoritiesCD
…127) of the cohort, of which 12% (n=92) were serious.Conclusion Risankizumab was effective in a large, real-world, medically refractory CD c…
paracetamolacetaminophenVisual Analogue Scalechronic painSwiss National Science FoundationalcoholismEthikkommission BernSwissmedic
…Introduction The analgesic and antipyretic paracetamol (acetaminophen) is generally considered safe in therapeutic dos…
TXLTongxinluo capsulePubMedacute coronary syndromes (ACS)CNKIWanfangVIPCochrane LibraryACS-PCImyocardial infarction+1 more
…dded to WM.Conclusion Current evidence suggests that adjunctive TXL may reduce key cardiovascular events and improve symptoms and q…